"Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data (vol 13, 912256, 2022)"
作者全名："Zhao, Quanfeng; Ma, Pan; Fu, Peishu; Wang, Jiayu; Wang, Kejing; Chen, Lin; Yang, Yang"
作者地址："[Zhao, Quanfeng; Ma, Pan; Fu, Peishu] Army Med Univ, Mil Med Univ 3, Affiliated Hosp 1, Dept Pharm, Chongqing, Peoples R China; [Wang, Jiayu; Wang, Kejing; Chen, Lin; Yang, Yang] Chongqing Med Univ, Women & Childrens Hosp, Dept Pharm, Chongqing, Peoples R China; [Wang, Jiayu; Wang, Kejing; Chen, Lin; Yang, Yang] Chongqing Hlth Ctr Women & Children, Dept Pharm, Chongqing, Peoples R China"
通信作者："Wang, KJ; Chen, L; Yang, Y (通讯作者)，Chongqing Med Univ, Women & Childrens Hosp, Dept Pharm, Chongqing, Peoples R China.; Wang, KJ; Chen, L; Yang, Y (通讯作者)，Chongqing Hlth Ctr Women & Children, Dept Pharm, Chongqing, Peoples R China."
来源：FRONTIERS IN PHARMACOLOGY
ESI学科分类：PHARMACOLOGY & TOXICOLOGY
WOS号：WOS:000860127900001
JCR分区：Q1
影响因子：5.6
年份：2022
卷号：13
期号：
开始页：
结束页：
文献类型：Correction
关键词：PARP inhibitors; myelodysplastic syndrome; acute myeloid leukemia; pharmacovigilance; real-world
摘要：
基金机构：
基金资助正文：
